Who is sponsoring NCT03122132?

NCT03122132 is sponsored by Hepa C.

What drugs are being tested in NCT03122132?

Interventions in NCT03122132: ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks.

What condition does NCT03122132 study?

NCT03122132 studies Hepatitis C Infection.

Is NCT03122132 still recruiting?

NCT03122132 is currently completed. Last updated 21 May 2018.

Last reviewed 2018-05-21 · How we verify

NCT03122132: 3D8

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

Completed Last updated 21 May 2018

What this trial tests

trial testing ombitasvir/paritaprevir/ritonavir 8 weeks in Hepatitis C Infection in 200 participants. Completed in 1 March 2018.

Timeline

20 February 2017

Primary endpoint
1 January 2018

1 March 2018

Quick facts

Lead sponsor	Hepa C
Status	Completed
Study type	OBSERVATIONAL
Enrollment	200
Start date	20 February 2017
Primary completion	1 January 2018
Estimated completion	1 March 2018
Sites	1 location across Spain

Drugs / interventions tested

ombitasvir/paritaprevir/ritonavir 8 weeks — full drug profile →
dasabuvir 8 weeks — full drug profile →

Conditions studied

Hepatitis C Infection — all drugs for Hepatitis C Infection →

Sponsor

Hepa C — full company profile →

Who can join

18 and older, any sex, with Hepatitis C Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus (HCV).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Puigvehí M, De Cuenca B, Viu A, Diago M, et al · · 2019 · cited 3× · PMID 30160363 · DOI 10.1111/liv.13950

Verify or expand the search:

Other recruiting trials for Hepatitis C Infection

Currently open trials in the same condition.

NCT02772003 — DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection · Phase 1 · active not recruiting

Other Hepa C trials

Trials by the same sponsor.

NCT03111966 — Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03122132 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hepa C
Last refreshed: 21 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03122132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing